Siren L.L.C. Raises Position in Stoke Therapeutics, Inc. $STOK

Key Points

• Siren L.L.C. increased its stake in Stoke Therapeutics by 12.4%, acquiring an additional 247,347 shares, bringing its total ownership to 2,247,347 shares valued at approximately $14.95 million.
• Stoke Therapeutics reported earnings per share of ($0.40), beating analysts' expectations, and had a revenue of $13.82 million for the quarter.
• Analysts have given Stoke Therapeutics a consensus rating of “Buy”, with a target price averaging $25.57, reflecting optimism about the stock's potential growth.

Siren L.L.C. grew its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 12.4% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 2,247,347 shares of the company's stock after buying an additional 247,347 shares during the quarter. Stoke Therapeutics makes up about 0.9% of Siren L.L.C.'s investment portfolio, making the stock its 29th largest holding. Siren L.L.C. owned approximately 4.12% of Stoke Therapeutics worth $14,945,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Jane Street Group LLC lifted its holdings in Stoke Therapeutics by 125.2% in the 1st quarter. Jane Street Group LLC now owns 26,978 shares of the company's stock worth $179,000 after buying an additional 15,001 shares during the period. Goldman Sachs Group Inc. lifted its holdings in Stoke Therapeutics by 21.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company's stock worth $11,053,000 after buying an additional 293,072 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Stoke Therapeutics by 5.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company's stock worth $162,000 after buying an additional 1,149 shares during the period. Jacobs Levy Equity Management Inc. purchased a new stake in Stoke Therapeutics in the 1st quarter worth approximately $2,376,000. Finally, Granahan Investment Management LLC lifted its stake in shares of Stoke Therapeutics by 16.3% in the 1st quarter. Granahan Investment Management LLC now owns 660,430 shares of the company's stock valued at $4,392,000 after purchasing an additional 92,741 shares during the period.

Insider Activity at Stoke Therapeutics

In related news, Director Edward M. Md Kaye sold 45,996 shares of the stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $20.13, for a total transaction of $925,899.48. Following the completion of the transaction, the director directly owned 91,585 shares of the company's stock, valued at approximately $1,843,606.05. This represents a 33.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Barry Ticho sold 5,501 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $19.87, for a total value of $109,304.87. Following the transaction, the insider directly owned 18,469 shares of the company's stock, valued at approximately $366,979.03. The trade was a 22.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 107,719 shares of company stock valued at $2,063,359. Insiders own 9.50% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Wedbush raised their target price on Stoke Therapeutics from $16.00 to $22.00 and gave the company an "outperform" rating in a research note on Wednesday, August 13th. BTIG Research set a $28.00 target price on Stoke Therapeutics and gave the company a "buy" rating in a research note on Monday, August 18th. Chardan Capital reiterated a "buy" rating and set a $24.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, August 13th. Jefferies Financial Group assumed coverage on Stoke Therapeutics in a report on Friday, July 18th. They issued a "buy" rating and a $30.00 target price for the company. Finally, Needham & Company LLC reissued a "buy" rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Tuesday, July 1st. Two investment analysts have rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $25.57.

Stoke Therapeutics Price Performance

Shares of NASDAQ:STOK traded up $0.02 during trading on Tuesday, hitting $23.42. 114,719 shares of the company's stock were exchanged, compared to its average volume of 811,800. The business's 50-day simple moving average is $16.28 and its 200 day simple moving average is $11.68. Stoke Therapeutics, Inc. has a 52-week low of $5.35 and a 52-week high of $24.60. The company has a market cap of $1.28 billion, a price-to-earnings ratio of 27.57 and a beta of 1.14.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.57) by $0.17. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%.The company had revenue of $13.82 million during the quarter, compared to analyst estimates of $31.51 million. On average, sell-side analysts anticipate that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.